A Phase 2 interventional study of Ruxolitinib and Prednisone or methylprednisolone in Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation. Completed at 38 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-24.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2016, is one of 13 in phase 2, and was the 3rd registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Bambino Gesù Hospital and Research Institute · Sites in Austria, Czechia, Denmark and 6 more countries
Ages 3 mo–25 yrs
Novartis Pharmaceuticals · Sites in China
Ages 12–100
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 4 · Phase 4 3
First in 2015; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 54 across the 27 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 27 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Graft vs Host Disease by Incyte Corporation: 1 open now, 1 under way, 1 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 12 studies in Graft vs Host Disease by Incyte Corporation, this one is the only one that started in 2016, is the only one in phase 2, and was the 2nd registered.
Incyte Corporation’s Graft vs Host Disease studies by the year they started, since 2015.
6 of the studies testing ruxolitinib in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07238712St. Petersburg State Pavlov Medical UniversityOptimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | 2026-12-10 |
| NCT06936566John LevineMAGIC Ruxolitinib for aGVHD | 2027-06-01 |
| NCT06008808Washington University School of MedicineRuxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | 2027-09-08 |
| NCT07796620Peking University People's HospitalSirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | 2027-09-30 |
| NCT07356245Ohio State University Comprehensive Cancer CenterRuxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | 2027-10-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, from their registry updates:
Among Incyte Corporation’s 12 in Graft vs Host Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with - acute GVHD, defined as any of the following:
Exclusion Criteria:
Severe organ dysfunction unrelated to underlying GVHD, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
Drug: Ruxolitinib · Drug: Prednisone or methylprednisolone
Also known as: Jakafi, INCB018424
Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
Overall Response Rate (ORR) at Day 28
Defined as the percentage of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).
Time frame: From baseline to Day 28
Overall Response Rate (ORR)
Defined as the percentage of participants demonstrating a CR, VGPR, or PR.
Time frame: From baseline to days 14, 56, and 100
Nonrelapse Mortality (NRM)
Defined as the proportion of subjects who died due to causes other than malignancy relapse.
Time frame: From baseline to Months 6, 9, 12, and 24
Percentage of Participants With Six-month Duration of Response (DOR)
Defined as the time from first response until graft-versus-host disease (GVHD) progression or death. DOR was assessed when all participants who were on the study completed the Day 180 visit.
Time frame: From Baseline up to 6 months
Percentage of Participants With Three-month DOR
Defined as the time from first response until GVHD progression or death. DOR was assessed when all participants who were on the study completed the Day 84 visit.
Time frame: From Baseline up to 3 months
Relapse Rate
Defined as the percentage of participants whose underlying malignancy relapsed.
Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Relapse-related Mortality Rate
Defined as the percentage of participants whose malignancy relapsed and had a fatal outcome.
Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Failure-free Survival (FFS)
Defined as the time from first dose of ruxolitinib to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).
Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Overall Survival (OS)
Defined as the time from study enrollment (first day of ruxolitinib treatment) to death due to any cause.
Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Number of Participants With Treatment-emergent Adverse Events (TEAES), Serious TEAEs, And Grade 3 or Higher TEAEs
AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Serious AE was any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. TEAE was an AE that was reported for the first time, or worsening of a pre-existing event after the first dose of study drug (until 30 days after the last dose of study drug). Severity of AEs was described and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03). Grade 3 and above would constitute a severe, life-threatening, or death event.
Time frame: From signing the informed consent form up to 30-35 days after the last dose of study treatment (up to 24 months)
This study was conducted at 26 study centers in the United States.
| Milestone | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Started | 71 |
| Completed | 0 |
| Not completed | 71 |
| Withdrew: Adverse event | 20 |
| Withdrew: Death | 7 |
| Withdrew: Physician decision | 23 |
| Withdrew: Progressive disease of gvhd | 7 |
| Withdrew: Relapse of underlying malignancy | 3 |
| Withdrew: Withdrawal by participant | 3 |
| Withdrew: Includes 2 participants who discontinued ruxolitinib treatment because of clinical improvement | 5 |
| Withdrew: Participants were transferred to commercial product. | 3 |
Defined as the percentage of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).
| Participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Responders - CR | 19 |
| Responders - VGPR | 7 |
| Responders - PR | 13 |
Defined as the percentage of participants demonstrating a CR, VGPR, or PR.
| percentage of participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Day 14 | 62.0 (49.7 to 73.2) |
| Day 56 | 36.6 (25.5 to 48.9) |
| Day 100 | 32.4 (21.8 to 44.5) |
Defined as the proportion of subjects who died due to causes other than malignancy relapse.
| percentage of participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| 6 months | 44.4 (32.5 to 55.7) |
| 9 months | 48.2 (35.8 to 59.5) |
| 12 months | 52.9 (39.6 to 64.5) |
| 24 months | 64.8 (46.0 to 78.5) |
Defined as the time from first response until graft-versus-host disease (GVHD) progression or death. DOR was assessed when all participants who were on the study completed the Day 180 visit.
| percentage of participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Percentage of Participants With Six-month Duration of Response (DOR) | 68.2 (49.6 to 81.2) |
Defined as the time from first response until GVHD progression or death. DOR was assessed when all participants who were on the study completed the Day 84 visit.
| percentage of participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Percentage of Participants With Three-month DOR | 84.5 (68.7 to 92.7) |
Defined as the percentage of participants whose underlying malignancy relapsed.
| percentage of participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Relapse Rate | 7.0 (2.3 to 15.7) |
Defined as the percentage of participants whose malignancy relapsed and had a fatal outcome.
| percentage of participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Relapse-related Mortality Rate | 5.6 (1.6 to 13.8) |
Defined as the time from first dose of ruxolitinib to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).
| days | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Failure-free Survival (FFS) | 85.0 (42.0 to 158.0) |
Defined as the time from study enrollment (first day of ruxolitinib treatment) to death due to any cause.
| days | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Overall Survival (OS) | 232.0 (93.0 to 675.0) |
AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Serious AE was any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. TEAE was an AE that was reported for the first time, or worsening of a pre-existing event after the first dose of study drug (until 30 days after the last dose of study drug). Severity of AEs was described and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03). Grade 3 and above would constitute a severe, life-threatening, or death event.
| Participants | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| TEAEs | 71 |
| Serious TEAEs | 59 |
| Grade 3 or Higher TEAEs | 69 |
Collected over From signing the informed consent form up to 30-35 days after the last dose of study treatment (up to 24 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib in Combination With Corticosteroids | 46/71 (64.8%) | 59/71 (83.1%) | 69/71 (97.2%) |
| Event | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| SepsisInfections and infestations | 9/71 |
| PyrexiaGeneral disorders | 8/71 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 7/71 |
| Lung infectionInfections and infestations | 5/71 |
| PneumoniaInfections and infestations | 5/71 |
| Pneumatosis intestinalisGastrointestinal disorders | 4/71 |
| BacteraemiaInfections and infestations | 4/71 |
| Acute kidney injuryRenal and urinary disorders | 4/71 |
| DiarrhoeaGastrointestinal disorders | 3/71 |
| Septic shockInfections and infestations | 3/71 |
| Event | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 45/71 |
| HypokalaemiaMetabolism and nutrition disorders | 34/71 |
| Oedema peripheralGeneral disorders | 33/71 |
| Platelet count decreasedInvestigations | 32/71 |
| Neutrophil count decreasedInvestigations | 27/71 |
| HypomagnesaemiaMetabolism and nutrition disorders | 24/71 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 24/71 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 24/71 |
| NauseaGastrointestinal disorders | 23/71 |
| FatigueGeneral disorders | 22/71 |
The efficacy evaluable population included all participants enrolled in the study.
| Age, Continuous(years) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Mean | 52.9 ± 14.18 |
| Age, Customized(Participants) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| < 65 years | 58 |
| ≥ 65 years | 13 |
| Sex: Female, Male(Participants) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Female | 36 |
| Male | 35 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 60 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 66 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Height(cm) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Mean | 170.2 ± 10.64 |
| Weight(kg) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Mean | 78.64 ± 21.651 |
| Body Mass Index (BMI)(kg/m^2) | Ruxolitinib in Combination With Corticosteroids |
|---|---|
| Mean | 26.83 ± 6.193 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Jan 2018, 13 months.
Results were first posted in Aug 2019, 1 year 6 months after primary completion. A results delay was requested in Jan 2019.
Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib